IL-13R alpha 2 CAR-T

IL-13R alpha 2 CAR-T is an autologous chimeric antigen receptor (CAR) T cell therapy engineered to target the interleukin-13 receptor subunit alpha 2 (IL-13Rα2), a protein overexpressed in several malignancies—most notably glioblastoma and other high-grade gliomas—with limited expression in normal tissues. Patient-derived T cells are genetically modified ex vivo using a lentiviral vector to express a synthetic receptor that combines an extracellular domain derived from interleukin-13 (often with mutations to enhance selectivity for IL-13Rα2 over the more ubiquitously expressed IL-13Rα1), fused to intracellular signaling domains such as CD3ζ and co-stimulatory molecules like 4‑1BB. Upon reinfusion into the patient following lymphodepleting chemotherapy, these engineered cells recognize and kill tumor cells expressing IL‑13Rα2 through direct cytotoxicity. Clinical studies have demonstrated safety and promising activity in recurrent glioblastoma when administered locoregionally or systemically; ongoing trials are evaluating its use in metastatic melanoma and other solid tumors[1][4][5][6][7].

Other names

Interleukin 13 receptor subunit alpha 2 chimeric antigen receptor T cell therapyInterleukin13 receptor subunit alpha 2 chimeric antigen receptor T cell therapyInterleukin-13 receptor subunit alpha 2 chimeric antigen receptor T cell therapyIL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells